Trial
NCT03343678
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Leukemia, Lymphocytic, Chronic, B-Cell
Intervention
Venetoclax
Why stopped
Company strategic decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-09